SF Intracity (9699.HK) issued a positive profit alert for the first half of 2026, forecasting profit attributable to owners of no less than RMB301 million, up at least 120% year on year. It also expects adjusted net profit of no less than RMB240 million, an increase of no less than 50%, and revenue of no less than RMB11,669 million, up at least 14%. The forecast falls under statutory disclosure requirements for Hong Kong-listed companies and directly reflects an improvement in the company’s fundamentals.

San Miguel Corp. completed a P30 billion follow-on offering of preferred shares on Monday and listed the securities on the Philippine Stock Exchange. The newly issued Series 2V, 2W and 2X preferred shares carry annual dividend rates of 8.0401%, 8.3570% and 8.6483%, respectively. The base offer covered 266.67 million shares, with the 133.33 million-share oversubscription option fully exercised. The company has now raised a total of P146.65 billion from five follow-on offerings.

Autolus Therapeutics said preliminary second-quarter 2026 net product revenue for AUCATZYL was about $45 million, with a year-to-date gross margin of roughly 35%. The company raised its FY 2026 sales guidance to $140–$150 million. It also announced a five-year credit facility with Perceptive Advisors of up to $250 million, with an initial $75 million funded. The update reflects stronger commercialization of its core product and improved cash-flow conditions.

Flutter Entertainment plc said its secondary listing in the U.K. has been cancelled as of 08:00 U.K. time on Aug. 3, 2026, ending both its place on the FCA’s Official List and trading on the London Stock Exchange’s main market. The company said its primary listing remains on the New York Stock Exchange under the ticker FLUT. Flutter said the move completes the streamlining plan it announced on June 12 and is a routine capital structure adjustment with no material changes to its business, financial position or governance.

Finnish insurer Sampo plc said it launched a buyback programme for up to EUR 350 million of its own A shares, starting on 7 May 2026, under an authorisation granted by its Annual General Meeting on 22 April 2026. The company said it announced the programme on 6 May 2026. After the disclosed transactions, Sampo held a total of 20,185,860 A shares, representing 0.76 per cent of its total number of shares. The move is part of the company’s regular capital return and can affect share supply and demand as well as per-share financial metrics.

Aktsiaselts Infortar repurchased its own shares on the Nasdaq Tallinn Stock Exchange from 27 July to 31 July 2026, with daily volumes ranging from 290 to 358 shares. The weighted average price ranged between €3.42 and €3.78 per share. The buyback was carried out under a stock exchange announcement published on 20 April 2026.

Leads Biolabs has received approval for an investigational new drug (IND) application for its PD-L1/4-1BB bispecific antibody in metastatic colorectal cancer (mCRC). The therapy is intended for microsatellite stable (MSS) or mismatch repair proficient (pMMR) mCRC, a group that represents about 95% of mCRC cases and has shown limited response to conventional immune checkpoint inhibitors. Colorectal cancer sees about 1.926 million new cases and 904,000 deaths globally each year, ranking as the third most common cancer and the second leading cause of cancer-related death.

Avista (NYSE: AVA) has filed its annual rate adjustment proposals with the Idaho Public Utilities Commission, covering items such as purchased natural gas costs, fixed costs, energy-efficiency programs, power costs and the Bonneville Power Administration Residential Exchange program, with no impact on earnings. The filings include a 3.0% decrease in the purchased gas cost adjustment and a 4.2% increase in the power cost adjustment. If approved, the proposed natural gas rate change would take effect Nov. 1, according to the company.

Moleculin Biotech (Nasdaq: MBRX) said it has completed an underwritten public offering raising $9.3 million. The deal included 12,376,667 shares of common stock (or equivalent prefunded warrants) and accompanying warrants. The warrants have an exercise price of $0.75 per share and expire five years after the initial exercise date.